PBS Review Recommends Broader Access to 14 Antidepressants
28 Oct 2026
At its September 2026 meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended changes to the PBS restrictions for 14 low-cost antidepressants. The proposed changes aim to better match subsidised access with current clinical practice in Australia.
The medicines reviewed include citalopram, clomipramine, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mianserin, mirtazapine, moclobemide, nortriptyline, paroxetine, sertraline and venlafaxine.
The PBAC’s public summary document is now available on the Australian Government’s PBS website.
PBS Review Recommends Broader Access to 14 Antidepressants
Source: Australian Government Department of Health, Disability and Ageing — Pharmaceutical Benefits Scheme (PBS). Review of low-cost PBS-listed antidepressants.
Categories
- MBS
- PBS
- The Department Of Health And Aged Care
- RACGP
- NIP
- AHPRA
- NSW Health
- Queensland Health
- Victoria Health
- Tasmania News
- Western Australia
- SA Health
- NT HEALTH
- Pharmacy Board Of Ahpra
- National Asthma Council
- NT
- AMA
- NACCHO
- BCNA
- Australian College Of Nurse Practitioners
- Asthma Australia
- LFA
- Palliative Care
- Primary Health Network
- AIHW
- Children's Health Queenland
- Kidney Health
- CHF
- MHC
- Gold Coast
- Tsa
- TGA
Popular Posts
Recent Posts
Tags
- Environmental health National Health and Climate Strategy environmental-health-national-health-and-climate-strategy